CRIS Current Research Information System

TOVOLI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.822
EU - Europa 3.155
AS - Asia 1.188
AF - Africa 272
SA - Sud America 22
OC - Oceania 6
Totale 9.465
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.806
GB - Regno Unito 659
IT - Italia 645
SE - Svezia 569
DE - Germania 436
VN - Vietnam 368
CN - Cina 295
SG - Singapore 235
IE - Irlanda 197
IN - India 196
TG - Togo 147
CH - Svizzera 132
FR - Francia 94
RU - Federazione Russa 93
UA - Ucraina 67
BG - Bulgaria 56
ZA - Sudafrica 53
EE - Estonia 44
FI - Finlandia 40
JO - Giordania 32
CI - Costa d'Avorio 30
NG - Nigeria 28
HR - Croazia 24
BE - Belgio 20
CA - Canada 14
ES - Italia 12
MK - Macedonia 11
AT - Austria 10
NL - Olanda 10
TW - Taiwan 10
GR - Grecia 9
TR - Turchia 9
CL - Cile 8
HK - Hong Kong 7
RO - Romania 7
BR - Brasile 6
CZ - Repubblica Ceca 6
DZ - Algeria 6
CO - Colombia 5
JP - Giappone 5
KR - Corea 5
AU - Australia 4
KZ - Kazakistan 4
PH - Filippine 4
PL - Polonia 4
SC - Seychelles 4
DK - Danimarca 3
IR - Iran 3
LB - Libano 3
PT - Portogallo 3
UZ - Uzbekistan 3
EG - Egitto 2
KE - Kenya 2
NZ - Nuova Zelanda 2
PK - Pakistan 2
AM - Armenia 1
AR - Argentina 1
BD - Bangladesh 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
HU - Ungheria 1
IQ - Iraq 1
KH - Cambogia 1
LK - Sri Lanka 1
MD - Moldavia 1
MX - Messico 1
MY - Malesia 1
NO - Norvegia 1
RS - Serbia 1
SA - Arabia Saudita 1
Totale 9.465
Salva come PNG Salva come JPEG
Città #
Fairfield 640
Southend 597
Chandler 526
Ashburn 452
Woodbridge 294
Wilmington 278
Seattle 265
Houston 244
Dong Ket 223
Singapore 206
Princeton 203
Cambridge 201
Dublin 197
Ann Arbor 159
Lomé 147
Bologna 140
Bern 124
New York 77
Berlin 67
Westminster 61
Los Angeles 55
Beijing 52
Sofia 52
Padova 49
Turin 45
Nanjing 43
Boardman 38
Bremen 38
Jinan 36
San Diego 36
Amman 32
Redmond 32
Helsinki 31
Santa Clara 31
Abidjan 30
Des Moines 29
Shenyang 29
Abeokuta 28
Milan 28
Redwood City 27
Saint Petersburg 27
Rome 26
Washington 24
Jacksonville 22
Falls Church 20
Florence 20
Brussels 18
Hebei 16
Chicago 15
Mülheim 14
London 13
Olalla 13
Bühl 12
Changsha 12
Nanchang 12
Frankfurt am Main 11
Medford 11
Haikou 10
Skopje 10
Tianjin 10
Vienna 10
Lappeenranta 9
Mountain View 9
Norwalk 9
Paris 9
Dearborn 8
Hangzhou 8
Jiaxing 8
Pune 8
Taipei 8
Toronto 8
Amsterdam 7
Germantown 7
Lübeck 7
Napoli 7
Parma 7
Zhengzhou 7
Dulles 6
Forlì 6
Fremont 6
Taiyuan 6
Esslingen am Neckar 5
Kuban 5
Moscow 5
Ningbo 5
San Francisco 5
Barcelona 4
Borgo Tossignano 4
Brno 4
Costa Mesa 4
Ferrara 4
Hialeah 4
Leawood 4
Liverpool 4
Mahé 4
Monmouth Junction 4
Muizenberg 4
Navsari 4
San Venanzo 4
Solarolo 4
Totale 6.399
Salva come PNG Salva come JPEG
Nome #
Serological tests in gluten sensitivity (nonceliac gluten intolerance). 184
Ablation for hepatocellular carcinoma: beyond the standard indications 184
null 164
Imaging-based diagnosis of benign lesions and pseudolesions in the cirrhotic liver 152
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention 148
Cholangiocarcinoma: From risk to prevention? 135
A case of inflammatory ascites. 133
Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis 128
Antibodies to deamidated gliadin peptides: an accurate predictor of coeliac disease in infancy. 128
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 126
Monofocal hepatocellular carcinoma: How much does size matter? 125
Clinical and diagnostic aspects of gluten related disorders 124
Celiac disease diagnosed through screening programs in at-risk adults is not associated with worse adherence to the gluten-free diet and might protect from osteopenia/osteoporosis 124
A relative deficiency of lysosomal acid lypase activity characterizes non-alcoholic fatty liver disease 123
Deamidated gliadin Peptide antibodies as a routine test for celiac disease: a prospective analysis. 121
Metabolic disorders across hepatocellular carcinoma in Italy 119
Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis 119
Clinical and immunological features of celiac disease in patients with Type 1 diabetes mellitus. 117
null 117
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 117
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: A multicenter real-life study 116
null 114
An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib 114
Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib 112
A seroimmunological profile of erosive hand osteoarthritis. 112
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. 110
From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma 110
More therapeutic alternatives for chronic idiopathic urticaria? 109
New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: A new diagnostic algorithm 109
Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet: beyond traditional metabolic factors 107
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 105
Systemic treatments for hepatocellular carcinoma: challenges and future perspectives 104
Imaging of colorectal liver metastases: New developments and pending issues 104
Autoimmune liver disorders and small-vessel vasculitis:four case reports and review of the literature 103
Rheumatoid arthritis: New monoclonal antibodies 103
Effect of gluten free diet on immune response to gliadin in patients with non-celiac gluten sensitivity. 103
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients 101
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 101
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 99
Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma 98
An uncommon focal liver lesion: Intrahepatic splenosis 98
Pattern of macrovascular invasion in hepatocellular carcinoma 97
Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma 96
Benefits, Open questions and Challenges of the use of Ultrasound in the COVID-19 pandemic eraThe views of a panel of worldwide international experts 96
Thrombotic thrombocytopenic purpura mimicking an acute meningoencephalitis. 95
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 92
Eosinophilic granulomatosis with polyangiitis of the major salivary glands: a case of sialadenitis in a young patient. 91
The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy 91
Hepatocellular carcinoma in non alcoholic fatty liver disease 86
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 85
Old and new serological tests for celiac disease screening. 83
Lenvatinib mesylate to treat hepatocellular carcinoma 83
null 82
Treatment of combined hepatocellular and cholangiocarcinoma 81
Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019 80
Regorafenib for the treatment of hepatocellular carcinoma 79
Hot topics in hepatocellular carcinoma 77
Fulminant type 1 autoimmune hepatitis in a recently diagnosed celiac disease patient. 76
What Future for Ultrasound in Medicine? 76
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 75
Gut-liver axis: an immune link between celiac disease and primary biliary cirrhosis. 75
null 75
Lung Ultrasound Is Often, but Not Always, Normal in Healthy Subjects: Considerations for {COVID}-19 Pandemic 75
Non-celiac gluten sensitivity: questions still to be answered despite increasing awareness. 75
Nailfold capillaroscopy in primary biliary cirrhosis: a useful tool for the early diagnosis of scleroderma. 73
Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: A tale of multiple confounders 73
Sensitivity of autologous serum skin test for chronic autoimmune urticaria 72
null 72
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 70
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 70
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (Targeted Oncology, (2020), 15, 6, (773-785), 10.1007/s11523-020-00757-3) 70
Fibromyalgia and coeliac disease: a media hype or an emerging clinical problem? 69
Anti-ganglioside antibodies and celiac disease 69
Telomerase reactivation is associated with hepatobiliary and pancreatic cancers 67
SAT-453-Effects of sorafenib on pancreatic volume and their clinical implications in patients with hepatocellular carcinoma 64
Ultrasound in the Assessment of Tumor Response in the Age of Targeted and Immuno-Oncology TherapiesBack to the Future 62
Immunotherapy with checkpoint inhibitors for hepatocellular carcinoma: Where are we now? 61
Non-alcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role 61
Anti-neutrophil cytoplasm antibodies (ANCA) in autoimmune diseases: A matter of laboratory technique and clinical setting 60
Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma 59
Hereditary breast cancer: Screening and risk reducing surgery 59
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 59
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. 58
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial 58
null 56
Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery 56
Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5) 56
Surrogate Markers for Antimitochondrial Antibody-Negative Primary Biliary Cholangitis 55
Experience with regorafenib in the treatment of hepatocellular carcinoma 54
Autoantibodies to speckled protein family in primary biliary cholangitis 52
Contrast-enhanced ultrasound of the liver in colorectal cancer: A useful tool in the right patient 51
Hepatocellular adenoma: An unsolved diagnostic enigma 49
The duration of the conventional chemoembolization for hepatocellular carcinoma: factors affecting the procedural time 48
The changing scenario of hepatocellular carcinoma in Italy: an update 47
Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis 46
Unexpected newborns in the liver : hemangiomatosis onset after hepatic resection of a giant cavernous hemangioma 45
Therapeutic targets to watch for fibromyalgia 44
Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease 43
Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers 42
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 42
Totale 8.933
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.435
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.435
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.582 0 40 16 76 167 170 241 269 284 166 76 77
2020/20211.548 209 87 64 57 191 106 30 77 134 79 68 446
2021/20222.065 139 42 94 108 175 112 50 167 106 154 646 272
2022/20232.582 230 357 126 305 162 212 163 133 441 67 169 217
2023/20241.046 49 140 76 76 112 216 84 86 65 72 48 22
2024/2025382 168 214 0 0 0 0 0 0 0 0 0 0
Totale 9.874